Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States
Market Cap
432.2M
52 Wk Range
$2.71 - $6.42
Previous Close
$4.16
Open
$4.15
Volume
1,396,783
Day Range
$4.00 - $4.29
Enterprise Value
280.8M
Cash
156.3M
Avg Qtr Burn
-44.03M
Insider Ownership
1.15%
Institutional Own.
86.68%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia | BLA Submission |